CLINUVEL expands DNA Repair Program
23 mars 2021 20h10 HE
|
Clinuvel Pharmaceuticals Limited
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) MELBOURNE, Australia, March 24, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its clinical program to...
PRA’s Center for Rare Diseases Launches Toolkit to Identify and Mitigate Risks to Rare Disease Clinical Programs
22 mars 2021 16h01 HE
|
PRA Health Sciences, Inc.
RALEIGH, N.C., March 22, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the launch of its Patient-Centric Trial Development Toolkit, available now to clinical...
Translate Bio Appoints Dr. Rand Sutherland as President
22 mars 2021 07h30 HE
|
Translate Bio, Inc.
-- 20 years of combined industry, medical and academic expertise in pulmonary and rare disease to support continued advancement of mRNA therapeutic pipeline -- LEXINGTON, Mass., March 22, 2021 ...
Sanionas styrelseordförande J. Donalds deBethizy och VD Rami Levin samt andra styrelseledamöter och ledande befattningshavare förvärvar aktier i ordinarie börshandel
19 mars 2021 12h30 HE
|
Saniona AB
PRESSMEDDELANDE 19 mars 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att styrelsens ordförande, VD och andra...
Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market
19 mars 2021 12h30 HE
|
Saniona AB
PRESS RELEASE March 19, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the Chairman and the CEO, as well as additional members...
ProQR to Present Results from Phase 1/2 Trial of QR-421a for Usher Syndrome
17 mars 2021 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
Saniona publicerar bokslutskommuniké för 2020
17 mars 2021 03h00 HE
|
Saniona AB
PRESSMEDDELANDE Finansiella höjdpunkter Jan - dec 2020 (jan - dec 2019, omräknat)Intäkter uppgick till 8,2 MSEK (7,2)Rörelseresultat uppgick till -159,4 MSEK (-93,6)Periodens resultat uppgick till...
Saniona publishes its year-end report for 2020
17 mars 2021 03h00 HE
|
Saniona AB
PRESS RELEASE Financial highlights Jan - Dec 2020 (Jan - Dec 2019 restated)Revenue was SEK 8.2 M (7.2 M)Operating loss was SEK -159.4 (-93.6 M)Net loss was SEK -73.4 M (-68.8 M)Earnings per share...
Saniona meddelar att data från studien med Tesomet på hypotalamisk fetma kommer att presenteras muntligt under ENDO 2021
15 mars 2021 08h00 HE
|
Saniona AB
PRESSMEDDELANDE 15 mars 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att data från bolagets kliniska Fas...
Saniona Announces Oral Presentation of Tesomet Data in Hypothalamic Obesity at ENDO 2021
15 mars 2021 08h00 HE
|
Saniona AB
PRESS RELEASE March 15, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that data from its Phase 2 clinical trial of Tesomet for...